Pharmacogenomic study on anti-VEGF medicine in treatment of macular Neovascular diseases: a study protocol for a prospective observational study

Pharmacogenomic study on anti-VEGF medicine in treatment of macular Neovascular diseases: a study protocol for a prospective observational study

Abstract Background Macular neovascular diseases can cause severe vision loss. A newly approved anti—VEGF drug Conbercept has shown good efficacy and safety in rigorous random controlled trials (RCT), however, it cannot fully reflect the clinical application of Conbercept in real world clinical prac...

Full description

Bibliographic Details
Main Authors: Jin Jing, Shen Yinchen, Chen Xia, Wang Jing, Chen Chong, Xu Xun, Huang Hengye, Liu Kun
Format: Article
Language:English
Published: BMC 2018-07-01
Series:BMC Ophthalmology
Subjects:
Anti-VEGF
Macular neovascular diseases
Conbercept
Pharmacogenomic
Online Access:http://link.springer.com/article/10.1186/s12886-018-0812-4

Internet

http://link.springer.com/article/10.1186/s12886-018-0812-4

Similar Items